All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Cytomegalovirus is a member of the herpes virus group, which includes herpes simplex virus types 1 and 2, varicella zoster virus (which causes chicken pox), and Epstein Barr virus (which causes infectious mononucleosis). These viruses share a characteristic ability to remain dormant within the body over a long period. CMV viral genes are co-ordinately expressed in groups at various times after infection. Early viral proteins are expressed in the nucleus of infected cells within 3 to 24 hours of infection prior to the commencement of viral DNA replication. This is followed by expression of the early intermediate genes, which encode enzymes required for viral DNA replication. After 48 to 72 hours, a number of late viral antigens may be demonstrated in the nuclei and cytoplasm of infected cells. pp65 is a 65kD phosphorylated glycoprotein and is the most abundant of the late antigens.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-L138 | Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#1), pCDTCR1 | CMV | TCRCD8-CMV#1 | Human | PLKMLNIPSINVHHYPSAAERKH | HLA-B3501 | Lentiviral | |
TCR-L139 | Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#4), pCDTCR1 | CMV | TCRCD8-CMV#4 | Human | NLVPMVATV | HLA-A0201 | Lentiviral | |
TCR-L140 | Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#8), pCDTCR1 | CMV | TCRCD8-CMV#8 | Human | NLVPMVATV | HLA-A0201 | Lentiviral | |
TCR-L141 | Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#9), pCDTCR1 | CMV | TCRCD8-CMV#9 | Human | NLVPMVATV | HLA-A0201 | Lentiviral | |
TCR-L142 | Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#10), pCDTCR1 | CMV | TCRCD8-CMV#10 | Human | NLVPMVATV | HLA-A0201 | Lentiviral | |
TCR-L143 | Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#11), pCDTCR1 | CMV | TCRCD8-CMV#11 | Human | NLVPMVATV | HLA-A0201 | Lentiviral | |
TCR-L144 | Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#12), pCDTCR1 | CMV | TCRCD8-CMV#12 | Human | NLVPMVATV | HLA-A0201 | Lentiviral | |
TCR-L145 | Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#14), pCDTCR1 | CMV | TCRCD8-CMV#14 | Human | NLVPMVATV | HLA-A0201 | Lentiviral | |
TCR-L146 | Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#15), pCDTCR1 | CMV | TCRCD8-CMV#15 | Human | NLVPMVATV | HLA-A0201 | Lentiviral | |
TCR-L147 | Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#16), pCDTCR1 | CMV | TCRCD8-CMV#16 | Human | NLVPMVATV | HLA-A0201 | Lentiviral | |
TCR-L148 | Human anti-CMV pp65 T cell receptor (TCRCD4-CMV#1), pCDTCR1 | CMV | TCRCD4-CMV#1 | Human | PLKMLNIPSINVHHYPSAAERKH | HLA-DRB1*0701 | Lentiviral | |
TCR-L149 | Human anti-CMV pp65 T cell receptor (TCRCD4-CMV#3), pCDTCR1 | CMV | TCRCD4-CMV#3 | Human | VELRQYDPVAALFFFDIDLLLQR | HLA-DRB1*0701 | Lentiviral | |
TCR-L150 | Human anti-CMV pp65 T cell receptor (TCRCD4-CMV#5), pCDTCR1 | CMV | TCRCD4-CMV#5 | Human | VELRQYDPVAALFFFDIDLLLQR | HLA-DRB1*0701 | Lentiviral |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION